ライフサイエンスコーパス: b.i.d.

1 s vehicle (t.i.d.: 25.9% [21/81, P = 0.028]; b.i.d.: 29.3% [24/82, P = 0.007] vs 11.9% [10/84]), with

2 mm [t.i.d.: 0.93; -1.47 to 3.32, P = 0.078; b.i.d.: 2.31; -0.08 to 4.70, P = 0.066]).

3 Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at do

4 nded to treatment with cenegermin t.i.d. and b.i.d. versus vehicle (t.i.d.: 25.9% [21/81, P = 0.028];

5 ent difference; 95% CI]: t.i.d., 2.60 mm and b.i.d., 3.99 mm vs 1.68 mm [t.i.d.: 0.93; -1.47 to 3.32,

6 max) and AUC) were observed with both od and b.i.d. dosing.

7 reasing doses of morphine (5-25 mg/kg, s.c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7

8 ete forebrain 5-HT (D,L-FEN, 20 mg/kg, s.c., b.i.d.).

9 .i.d.; 20 mcg/mL), cenegermin 2 times daily (b.i.d.; 20 mcg/mL) and vehicle once daily, or vehicle t.

10 0 mg q.d. for 3 days, or 600 mg twice daily (b.i.d.) for 3 days or to receive a single dose of flucon

11 0 mg q.d. for 3 days, or 600 mg twice daily (b.i.d.) for 3 days, or a single dose of fluconazole 150

12 ceived oral savolitinib [300 mg twice daily (b.i.d.) or once daily (o.d.), or 600 mg o.d.] plus osime

13 ed to receive alectinib [600 mg twice daily (b.i.d.)] or crizotinib (250 mg b.i.d.) until disease pro

14 andard abemaciclib dose [150 mg twice daily (b.i.d.)], potentially leading to early treatment discont

15 (q.d.) (251); netarsudil 0.02% twice a day (b.i.d.) (254); or timolol 0.5% b.i.d.

16 ing SCH66336 doses given orally twice a day (b.i.d.) for 7 days out of every 3 weeks.

17 nts received once daily (od) or twice a day (b.i.d.) GSK3326595 in doses ranging from 12.5 to 600 mg/

18 r =2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days.

19 once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.

20 at doses of 237 micromol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus

21 o 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidaz

22 (q.d.), 2.5-10 mg/kg of R-FB twice per day (b.i.d.), and 5 mg/kg of R-FB b.i.d. challenged with a hi

23 an-treated (5 days at 10 mg kg-1 bis in die (b.i.d.)) rats decreased renal blood flow by 46 and 29 %

24 or CEP-5214 to CD-1 mice at 23.8 mg/kg/dose b.i.d. resulted in a reversible inhibition of VEGF-R2/FL

25 p.o. of CEP-7055 at 2.57 to 23.8 mg/kg/dose b.i.d. resulted in dose-related reductions in neovascula

26 CEP-7055 at doses of 11.9 to 23.8 mg/kg/dose b.i.d. resulted in significant inhibition (50-90% maximu

27 twice per day (b.i.d.), and 5 mg/kg of R-FB b.i.d. challenged with a high saturated fat diet.

28 A dose of 5 mg/kg R-FB b.i.d. was able to overcome the doubling in tumor number

29 days with 10 mg/kg R-FB q.d. or 5 mg/kg R-FB b.i.d..

30 i.d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n = 29).

31 ther a high dose BDP/F 100/6 two inhalations b.i.d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n

32 ther, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia in

33 MPTP (24 mg/kg b.i.d. for 4 doses) increased striatal zif268 expression

34 nimal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days.

35 nts in mice revealed that a dose of 30 mg/kg b.i.d. results in free levels of GB1908 in plasma over g

36 models of contact hypersensitivity (1 mg/kg b.i.d.) and house dust (20 mg/kg q.d.) when dosed orally

37 decrease in weight gain observed at 36 mg/kg b.i.d.).

38 e at the time of transplantation was 5 mg/kg b.i.d.; doses were titrated to target trough levels.

39 ived either placebo or rhIGF-I (50 microg/kg b.i.d.) for 19 days in a randomized, double-blind, paral

40 administration of rhIGF-I (100 micrograms/kg b.i.d.) significantly lowered blood glucose.

41 c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 days.

42 mer providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania infantum hamster model

43 vanserin (3 mg/kg), or haloperidol (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (d

44 (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day1-7), followed by a 7-day washout

45 (A) receptor blockade (BMS 193884, 50 mg/kg, b.i.d.) for the last week of pacing; n=6; 3) CHF/ET(A)-L

46 ) receptor blockade (BMS 193884, 12.5 mg/kg, b.i.d.) for the last week, n=6; and 4) Control: n=8.

47 n mice when administered orally at 25 mg/kg, b.i.d., for 4 days.

48 ritoneal injection of TRK820 (0.1-10 mug/kg, b.i.d.) significantly inhibited tumor growth by suppress

49 cyclosporine microemulsion (Neoral) 60 mg/kg/b.i.d. on days +1 to +3 with dose adjusted by blood leve

50 /day) and either placebo or pindolol (5.0 mg b.i.d. or 2.5 mg t.i.d.), for 6 weeks, in a randomized,

51 ne, followed by maintenance on placebo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

52 ct human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

53 nd MMF dosing were 5 to 7 ng/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d.

54 The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated do

55 posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic acid was detected by RT

56 b.i.d. for 2 weeks, then escalated to 100 mg b.i.d. for 2 weeks, then escalated to the final dose lev

57 ences: sequence A (n = 15) Org 26576 (100 mg b.i.d.) for 3 weeks, followed by a 2-week placebo crosso

58 nicotinic receptor PAM JNJ-39393406 (100 mg b.i.d.) or placebo (double-blind, counter-balanced).

59 PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivit

60 Org 26576 (100 mg b.i.d.) was superior to placebo in treating symptoms of

61 7 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

62 lacebo followed by 3 weeks Org 26576 (100 mg b.i.d.); sequence C (n = 18) Org 26576 flexible dose (10

63 al bleeding was lower with dabigatran 110 mg b.i.d. (aHR: 0.60, 95% CI: 0.37 to 0.93) compared with w

64 was seen with both dabigatran doses (110 mg b.i.d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d.,

65 was lower with both dabigatran doses (110 mg b.i.d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d.,

66 tly lower with both dabigatran doses (110 mg b.i.d., propensity-match group stratified hazard ratio [

67 jority (70.8%) reached and maintained 150 mg b.i.d. dosing.

68 en escalated to the final dose level (150 mg b.i.d.).

69 .d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40).

70 .d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70).

71 nfidence interval [CI]: 0.65 to 0.95; 150 mg b.i.d., aHR: 0.57, 95% CI: 0.40 to 0.80), when compared

72 ted to achieve glycemic control (< or =20 mg b.i.d. or q.d.).

73 either placebo capsules + AFS or LDD (20 mg b.i.d.) + AFS.

74 rofen (LDF) alone, 50 mg q.d.; 2) SDD (20 mg b.i.d.) alone; or 3) a combination of SDD plus LDF (comb

75 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.

76 ng sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19).

77 twice daily (b.i.d.)] or crizotinib (250 mg b.i.d.) until disease progression, unacceptable toxicity

78 FISH10+ status receiving savolitinib 300 mg b.i.d. plus osimertinib (primary efficacy population).

79 simertinib 80 mg o.d., or savolitinib 300 mg b.i.d. plus placebo.

80 However, Org 26576 (100-300 mg b.i.d.) did not confirm these results.

81 (n = 18) Org 26576 flexible dose (100-300 mg b.i.d.) for 3 weeks, then 5 weeks placebo; sequence D (n

82 bo followed by 3 weeks Org 26576 (100-300 mg b.i.d.).

83 for future testing on this schedule (350 mg b.i.d.) but also provides the first evidence of successf

84 hree months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo pe

85 6) or placebo (n=2), the second cohort 40 mg b.i.d. (n=6) or placebo (n=2), and the third cohort 40 m

86 y on PPI and the dose was increased to 40 mg b.i.d. 31 consecutive patients with typical reflux sympt

87 nidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonuclei

88 ies trial, the effects of rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. were compared with those

89 Participants initiated abemaciclib at 50 mg b.i.d. for 2 weeks, then escalated to 100 mg b.i.d. for

90 ial human laboratory efficacy of IBUD (50 mg b.i.d.) on primary measures of subjective response to al

91 tes treated with either vildaglipitin (50 mg b.i.d.) or placebo for 10 days using a double-blind, pla

92 bo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

93 with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.).

94 . in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. in group B.

95 One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while the other group re

96 other group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.

97 T1161 600 mg q.d. (85.7%), and VT1161 600 mg b.i.d. (78.6%) groups versus the fluconazole group (62.5

98 1161 600 mg q.d. (85.7%), and VT-1161 600 mg b.i.d. (78.6%) groups vs the fluconazole group (62.5%);

99 oses of 800 mg o.d., 1200 mg o.d., or 600 mg b.i.d. (n = 42), objective response rate was 21.4% (95%

100 d AMG 193 at doses 40-1600 mg o.d. or 600 mg b.i.d. The most common treatment-related adverse events

101 o the estimated human dose range of 10-75 mg b.i.d. to achieve 90% alpha(v)beta(6) target engagement

102 rapy with aerosolized colistin sodium (75 mg b.i.d.), and intravenous antibiotics were eliminated.

103 2 diabetic subjects taking metformin 850 mg b.i.d. versus placebo.

104 , dogs were treated with 30 mL of mouthrinse b.i.d. for 28 days.

105 5-17.9 mm Hg for netarsudil q.d., netarsudil b.i.d., and timolol, respectively, over 12 months.

106 q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET

107 ed 24 h after induction of MR (60 mg/kg p.o. b.i.d.) and continued for three months.

108 control received tacrolimus (0.15 mg/kg p.o. b.i.d.) and the same steroid taper.

109 1 g p.o. b.i.d.), tacrolimus (0.1 mg/kg p.o. b.i.d.), and a standard steroid taper.

110 ts in the study group received MMF (1 g p.o. b.i.d.), tacrolimus (0.1 mg/kg p.o. b.i.d.), and a stand

111 p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was begun at transplantation and continued

112 Two doses of VEGFR2-TKI (25 mg/kg, p.o., b.i.d.) resulted in a decrease of V(b) to 1.3 +/- 0.3%.

113 aily postischemic oral dosing (1 mg/kg p.o., b.i.d., beginning at 1 h after insult) decreased the 28-

114 P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overe

115 atment with ganciclovir (GCV), 10 mg/kg i.p. b.i.d. for 6 days.

116 ts that had received cocaine (20 mg/kg, i.p. b.i.d.) or saline since birth.

117 d UCP-DTA mice with leptin (300 microg i.p., b.i.d.) and compared their response with that of leptin-

118 We tested the effect of LSF (100 mg/kg i.p., b.i.d.) on multilineage regeneration after high-dose 5-F

119 ob/ob and FVB control mice (30 microg i.p., b.i.d.).

120 day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg

121 ted with 40 mg pantoprazole (PPI) or placebo b.i.d. was performed.

122 arteether as controls, were administered po b.i.d. (128 mg/kg/day) to P. berghei-infected mice on da

123 dministered either CsA or CsA-ME at the same b.i.d. dosage as their maintenance therapy.

124 ication administered 20 mg/kg subcutaneously b.i.d..

125 nificance (set at P < 0.025) observed in the b.i.d. group.